公开(公告)号：US11028084B2

公开(公告)日：2021-06-08

申请号：US16349580

申请日：2017-11-14

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft ,  Forschungsverbund Berlin e.V.

发明人： Claus Scheidereit ,  Michael Willenbrock ,  Peter Lindemann ,  Silke Radetzki ,  Jens-Peter Von Kries ,  Marc Nazare

IPC分类号： C07D471/04 ,  A61P35/00 ,  C07D209/56 ,  C07D221/06 ,  C07D471/14 ,  C07D487/04 ,  C07D471/16

摘要： A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.

公开(公告)号：US20190276452A1

公开(公告)日：2019-09-12

申请号：US16349580

申请日：2017-11-14

申请人： Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft ,  Forschungsverbund Berlin e.V.

发明人： Claus Scheidereit ,  Michael Willenbrock ,  Peter Lindemann ,  Silke Radetzki ,  Jens-Peter Von Kries ,  Marc Nazare

IPC分类号： C07D471/04 ,  C07D471/14 ,  C07D209/56 ,  C07D487/04 ,  C07D221/06 ,  A61P35/00

摘要： A method is for treatment of a disease associated with genotoxic stress-induced inhibitor of nuclear factor-κB kinase/nuclear factor kappa-light chain enhancer of activated B cells (IKK/NF-κB) signaling. The method can include administering a compound to a subject having a cancer exhibiting genotoxic stress induced IKK/NF-κB activation.